- The S&P 500 Index, Dow Jones Industrial Average, Nasdaq Composite Index, Nasdaq 100 Index and Russell 2000 Index all fell, while the Cboe Volatility Index rose.
- Amundi is seeking to purchase dips after missing out on the stock rally.
- Apple is considering the use of robots as a new venture after its car project didn’t succeed.
- Redstone has a tentative agreement to sell its stake in Paramount to Skydance.
- Initial applications for US unemployment benefits have reached their highest since January, indicating an increase in job cuts.
- The upcoming payrolls figures are expected to reveal a gain of approximately 213,000 in nonfarm payrolls, the slowest pace since November.
- Lamb Weston has reduced its fiscal-year sales and profit forecasts due to issues with its new enterprise resource planning system and soft restaurant traffic trends.
- Conagra Brands’ volume performance is improving, leading the company to increase its operating margin forecast for the year.
- Amylyx is withdrawing its ALS drug from the market and downsizing its workforce, while MacroGenics is seeing promising interim data from its prostate cancer study.
- Lululemon shares are struggling due to a price target cut by Jefferies analyst Randal Konik.
- HubSpot shares have risen 5% on reports that Google parent Alphabet is considering making an offer for the company.
- Hertz Global Holdings shares are falling after Goldman Sachs downgraded its rating from neutral to sell.
- Block’s shares are also falling after a downgrade from Morgan Stanley.
- European stocks are near record highs, and most emerging Asian currencies are gaining as traders anticipate US non-farm payroll data.
A look at Fresenius & KGaA Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 5 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Fresenius SE & Co KGaA, a global health care group, has received a promising long-term outlook based on the Smartkarma Smart Scores. The company has been given a score of 5 for Value, indicating a strong value proposition for investors. Additionally, with a score of 4 for Dividend, Fresenius & KGaA is also expected to provide good returns to its shareholders through dividends.
The company has also been given a score of 3 for Growth, Resilience, and Momentum, demonstrating its potential for future growth and stability. Fresenius & KGaA offers a wide range of products and services for dialysis, hospital care, and medical care at home, including equipment, systems, and pharmaceuticals. With its strong performance across various factors, the company is well-positioned for long-term success in the health care industry.
Summary: Fresenius SE & Co KGaA is a global health care group that offers a diverse portfolio of products and services for dialysis, hospital care, and medical care at home. The company has received positive long-term outlook based on its high Smartkarma Smart Scores, including a score of 5 for Value and 4 for Dividend. With a score of 3 for Growth, Resilience, and Momentum, Fresenius & KGaA is expected to continue its success in the health care market.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
